Global Ankylosing Spondylitis Medication Market Research Report 2023
This report aims to provide a comprehensive presentation of the global market for Ankylosing Spondylitis Medication, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ankylosing Spondylitis Medication.
The Ankylosing Spondylitis Medication market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Ankylosing Spondylitis Medication market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ankylosing Spondylitis Medication manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Ankylosing Spondylitis Medication manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Ankylosing Spondylitis Medication in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The Ankylosing Spondylitis Medication market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Ankylosing Spondylitis Medication market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ankylosing Spondylitis Medication manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
- Pfizer
- UCB Biopharma
- Hetero Biopharma
- Amgen
- Cadila Pharmaceuticals
- Torrent Pharmaceuticals
- Cipla
- Emcure Pharmaceuticals
- Boehringer Ingelheim
- Zhejiang Hisun Pharmaceuticals
- Biocad
- AbbVie
- Mycenax Biotech
- Celltrion
- Gilead Sciences
- Jiangsu HengRui Medicine Co., Ltd.
- Izana Bioscience
- Suzhou Zelgen Biopharmaceuticals
- Iltoo Pharma
- Kinevant Sciences
- Qyuns Therapeutics
- Akeso Biopharma
- Nimbus Therapeutics
- Enzene Biosciences
- Xbrane Biopharma
- Dice molecules
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Corticosteroids
- Disease-Modifying Antirheumatic Drugs (DMARDs)
- Biologics (TNF-blocking Agents)
- Sulfasalazine
- Methotrexate
- Others
- Hospital
- Specialist Clinic
- North America
- United States
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Southeast Asia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Ankylosing Spondylitis Medication manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Ankylosing Spondylitis Medication in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 ANKYLOSING SPONDYLITIS MEDICATION MARKET OVERVIEW
1.1 Product Overview and Scope of Ankylosing Spondylitis Medication
1.2 Ankylosing Spondylitis Medication Segment by Type
1.2.1 Global Ankylosing Spondylitis Medication Market Value Comparison by Type (2023-2029)
1.2.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
1.2.3 Corticosteroids
1.2.4 Disease-Modifying Antirheumatic Drugs (DMARDs)
1.2.5 Biologics (TNF-blocking Agents)
1.2.6 Sulfasalazine
1.2.7 Methotrexate
1.2.8 Others
1.3 Ankylosing Spondylitis Medication Segment by Application
1.3.1 Global Ankylosing Spondylitis Medication Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Specialist Clinic
1.4 Global Ankylosing Spondylitis Medication Market Size Estimates and Forecasts
1.4.1 Global Ankylosing Spondylitis Medication Revenue 2018-2029
1.4.2 Global Ankylosing Spondylitis Medication Sales 2018-2029
1.4.3 Global Ankylosing Spondylitis Medication Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 ANKYLOSING SPONDYLITIS MEDICATION MARKET COMPETITION BY MANUFACTURERS
2.1 Global Ankylosing Spondylitis Medication Sales Market Share by Manufacturers (2018-2023)
2.2 Global Ankylosing Spondylitis Medication Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Ankylosing Spondylitis Medication Average Price by Manufacturers (2018-2023)
2.4 Global Ankylosing Spondylitis Medication Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Ankylosing Spondylitis Medication, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Ankylosing Spondylitis Medication, Product Type & Application
2.7 Ankylosing Spondylitis Medication Market Competitive Situation and Trends
2.7.1 Ankylosing Spondylitis Medication Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Ankylosing Spondylitis Medication Players Market Share by Revenue
2.7.3 Global Ankylosing Spondylitis Medication Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 ANKYLOSING SPONDYLITIS MEDICATION RETROSPECTIVE MARKET SCENARIO BY REGION
3.1 Global Ankylosing Spondylitis Medication Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Ankylosing Spondylitis Medication Global Ankylosing Spondylitis Medication Sales by Region: 2018-2029
3.2.1 Global Ankylosing Spondylitis Medication Sales by Region: 2018-2023
3.2.2 Global Ankylosing Spondylitis Medication Sales by Region: 2024-2029
3.3 Global Ankylosing Spondylitis Medication Global Ankylosing Spondylitis Medication Revenue by Region: 2018-2029
3.3.1 Global Ankylosing Spondylitis Medication Revenue by Region: 2018-2023
3.3.2 Global Ankylosing Spondylitis Medication Revenue by Region: 2024-2029
3.4 North America Ankylosing Spondylitis Medication Market Facts & Figures by Country
3.4.1 North America Ankylosing Spondylitis Medication Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Ankylosing Spondylitis Medication Sales by Country (2018-2029)
3.4.3 North America Ankylosing Spondylitis Medication Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Ankylosing Spondylitis Medication Market Facts & Figures by Country
3.5.1 Europe Ankylosing Spondylitis Medication Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Ankylosing Spondylitis Medication Sales by Country (2018-2029)
3.5.3 Europe Ankylosing Spondylitis Medication Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Ankylosing Spondylitis Medication Market Facts & Figures by Country
3.6.1 Asia Pacific Ankylosing Spondylitis Medication Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Ankylosing Spondylitis Medication Sales by Country (2018-2029)
3.6.3 Asia Pacific Ankylosing Spondylitis Medication Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Ankylosing Spondylitis Medication Market Facts & Figures by Country
3.7.1 Latin America Ankylosing Spondylitis Medication Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Ankylosing Spondylitis Medication Sales by Country (2018-2029)
3.7.3 Latin America Ankylosing Spondylitis Medication Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Ankylosing Spondylitis Medication Market Facts & Figures by Country
3.8.1 Middle East and Africa Ankylosing Spondylitis Medication Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Ankylosing Spondylitis Medication Sales by Country (2018-2029)
3.8.3 Middle East and Africa Ankylosing Spondylitis Medication Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 SEGMENT BY TYPE
4.1 Global Ankylosing Spondylitis Medication Sales by Type (2018-2029)
4.1.1 Global Ankylosing Spondylitis Medication Sales by Type (2018-2023)
4.1.2 Global Ankylosing Spondylitis Medication Sales by Type (2024-2029)
4.1.3 Global Ankylosing Spondylitis Medication Sales Market Share by Type (2018-2029)
4.2 Global Ankylosing Spondylitis Medication Revenue by Type (2018-2029)
4.2.1 Global Ankylosing Spondylitis Medication Revenue by Type (2018-2023)
4.2.2 Global Ankylosing Spondylitis Medication Revenue by Type (2024-2029)
4.2.3 Global Ankylosing Spondylitis Medication Revenue Market Share by Type (2018-2029)
4.3 Global Ankylosing Spondylitis Medication Price by Type (2018-2029)
5 SEGMENT BY APPLICATION
5.1 Global Ankylosing Spondylitis Medication Sales by Application (2018-2029)
5.1.1 Global Ankylosing Spondylitis Medication Sales by Application (2018-2023)
5.1.2 Global Ankylosing Spondylitis Medication Sales by Application (2024-2029)
5.1.3 Global Ankylosing Spondylitis Medication Sales Market Share by Application (2018-2029)
5.2 Global Ankylosing Spondylitis Medication Revenue by Application (2018-2029)
5.2.1 Global Ankylosing Spondylitis Medication Revenue by Application (2018-2023)
5.2.2 Global Ankylosing Spondylitis Medication Revenue by Application (2024-2029)
5.2.3 Global Ankylosing Spondylitis Medication Revenue Market Share by Application (2018-2029)
5.3 Global Ankylosing Spondylitis Medication Price by Application (2018-2029)
6 KEY COMPANIES PROFILED
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer Ankylosing Spondylitis Medication Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 UCB Biopharma
6.2.1 UCB Biopharma Corporation Information
6.2.2 UCB Biopharma Description and Business Overview
6.2.3 UCB Biopharma Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.2.4 UCB Biopharma Ankylosing Spondylitis Medication Product Portfolio
6.2.5 UCB Biopharma Recent Developments/Updates
6.3 Hetero Biopharma
6.3.1 Hetero Biopharma Corporation Information
6.3.2 Hetero Biopharma Description and Business Overview
6.3.3 Hetero Biopharma Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Hetero Biopharma Ankylosing Spondylitis Medication Product Portfolio
6.3.5 Hetero Biopharma Recent Developments/Updates
6.4 Amgen
6.4.1 Amgen Corporation Information
6.4.2 Amgen Description and Business Overview
6.4.3 Amgen Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Amgen Ankylosing Spondylitis Medication Product Portfolio
6.4.5 Amgen Recent Developments/Updates
6.5 Cadila Pharmaceuticals
6.5.1 Cadila Pharmaceuticals Corporation Information
6.5.2 Cadila Pharmaceuticals Description and Business Overview
6.5.3 Cadila Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Cadila Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolio
6.5.5 Cadila Pharmaceuticals Recent Developments/Updates
6.6 Torrent Pharmaceuticals
6.6.1 Torrent Pharmaceuticals Corporation Information
6.6.2 Torrent Pharmaceuticals Description and Business Overview
6.6.3 Torrent Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Torrent Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolio
6.6.5 Torrent Pharmaceuticals Recent Developments/Updates
6.7 Cipla
6.6.1 Cipla Corporation Information
6.6.2 Cipla Description and Business Overview
6.6.3 Cipla Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Cipla Ankylosing Spondylitis Medication Product Portfolio
6.7.5 Cipla Recent Developments/Updates
6.8 Emcure Pharmaceuticals
6.8.1 Emcure Pharmaceuticals Corporation Information
6.8.2 Emcure Pharmaceuticals Description and Business Overview
6.8.3 Emcure Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Emcure Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolio
6.8.5 Emcure Pharmaceuticals Recent Developments/Updates
6.9 Boehringer Ingelheim
6.9.1 Boehringer Ingelheim Corporation Information
6.9.2 Boehringer Ingelheim Description and Business Overview
6.9.3 Boehringer Ingelheim Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Boehringer Ingelheim Ankylosing Spondylitis Medication Product Portfolio
6.9.5 Boehringer Ingelheim Recent Developments/Updates
6.10 Zhejiang Hisun Pharmaceuticals
6.10.1 Zhejiang Hisun Pharmaceuticals Corporation Information
6.10.2 Zhejiang Hisun Pharmaceuticals Description and Business Overview
6.10.3 Zhejiang Hisun Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Zhejiang Hisun Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolio
6.10.5 Zhejiang Hisun Pharmaceuticals Recent Developments/Updates
6.11 Biocad
6.11.1 Biocad Corporation Information
6.11.2 Biocad Ankylosing Spondylitis Medication Description and Business Overview
6.11.3 Biocad Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Biocad Ankylosing Spondylitis Medication Product Portfolio
6.11.5 Biocad Recent Developments/Updates
6.12 AbbVie
6.12.1 AbbVie Corporation Information
6.12.2 AbbVie Ankylosing Spondylitis Medication Description and Business Overview
6.12.3 AbbVie Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.12.4 AbbVie Ankylosing Spondylitis Medication Product Portfolio
6.12.5 AbbVie Recent Developments/Updates
6.13 Mycenax Biotech
6.13.1 Mycenax Biotech Corporation Information
6.13.2 Mycenax Biotech Ankylosing Spondylitis Medication Description and Business Overview
6.13.3 Mycenax Biotech Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Mycenax Biotech Ankylosing Spondylitis Medication Product Portfolio
6.13.5 Mycenax Biotech Recent Developments/Updates
6.14 Celltrion
6.14.1 Celltrion Corporation Information
6.14.2 Celltrion Ankylosing Spondylitis Medication Description and Business Overview
6.14.3 Celltrion Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Celltrion Ankylosing Spondylitis Medication Product Portfolio
6.14.5 Celltrion Recent Developments/Updates
6.15 Gilead Sciences
6.15.1 Gilead Sciences Corporation Information
6.15.2 Gilead Sciences Ankylosing Spondylitis Medication Description and Business Overview
6.15.3 Gilead Sciences Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Gilead Sciences Ankylosing Spondylitis Medication Product Portfolio
6.15.5 Gilead Sciences Recent Developments/Updates
6.16 Jiangsu HengRui Medicine Co., Ltd.
6.16.1 Jiangsu HengRui Medicine Co., Ltd. Corporation Information
6.16.2 Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Description and Business Overview
6.16.3 Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Product Portfolio
6.16.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
6.17 Izana Bioscience
6.17.1 Izana Bioscience Corporation Information
6.17.2 Izana Bioscience Ankylosing Spondylitis Medication Description and Business Overview
6.17.3 Izana Bioscience Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Izana Bioscience Ankylosing Spondylitis Medication Product Portfolio
6.17.5 Izana Bioscience Recent Developments/Updates
6.18 Suzhou Zelgen Biopharmaceuticals
6.18.1 Suzhou Zelgen Biopharmaceuticals Corporation Information
6.18.2 Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Description and Business Overview
6.18.3 Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Product Portfolio
6.18.5 Suzhou Zelgen Biopharmaceuticals Recent Developments/Updates
6.19 Iltoo Pharma
6.19.1 Iltoo Pharma Corporation Information
6.19.2 Iltoo Pharma Ankylosing Spondylitis Medication Description and Business Overview
6.19.3 Iltoo Pharma Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Iltoo Pharma Ankylosing Spondylitis Medication Product Portfolio
6.19.5 Iltoo Pharma Recent Developments/Updates
6.20 Kinevant Sciences
6.20.1 Kinevant Sciences Corporation Information
6.20.2 Kinevant Sciences Ankylosing Spondylitis Medication Description and Business Overview
6.20.3 Kinevant Sciences Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Kinevant Sciences Ankylosing Spondylitis Medication Product Portfolio
6.20.5 Kinevant Sciences Recent Developments/Updates
6.21 Qyuns Therapeutics
6.21.1 Qyuns Therapeutics Corporation Information
6.21.2 Qyuns Therapeutics Ankylosing Spondylitis Medication Description and Business Overview
6.21.3 Qyuns Therapeutics Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Qyuns Therapeutics Ankylosing Spondylitis Medication Product Portfolio
6.21.5 Qyuns Therapeutics Recent Developments/Updates
6.22 Akeso Biopharma
6.22.1 Akeso Biopharma Corporation Information
6.22.2 Akeso Biopharma Ankylosing Spondylitis Medication Description and Business Overview
6.22.3 Akeso Biopharma Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.22.4 Akeso Biopharma Ankylosing Spondylitis Medication Product Portfolio
6.22.5 Akeso Biopharma Recent Developments/Updates
6.23 Nimbus Therapeutics
6.23.1 Nimbus Therapeutics Corporation Information
6.23.2 Nimbus Therapeutics Ankylosing Spondylitis Medication Description and Business Overview
6.23.3 Nimbus Therapeutics Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Nimbus Therapeutics Ankylosing Spondylitis Medication Product Portfolio
6.23.5 Nimbus Therapeutics Recent Developments/Updates
6.24 Enzene Biosciences
6.24.1 Enzene Biosciences Corporation Information
6.24.2 Enzene Biosciences Ankylosing Spondylitis Medication Description and Business Overview
6.24.3 Enzene Biosciences Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.24.4 Enzene Biosciences Ankylosing Spondylitis Medication Product Portfolio
6.24.5 Enzene Biosciences Recent Developments/Updates
6.25 Xbrane Biopharma
6.25.1 Xbrane Biopharma Corporation Information
6.25.2 Xbrane Biopharma Ankylosing Spondylitis Medication Description and Business Overview
6.25.3 Xbrane Biopharma Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.25.4 Xbrane Biopharma Ankylosing Spondylitis Medication Product Portfolio
6.25.5 Xbrane Biopharma Recent Developments/Updates
6.26 Dice molecules
6.26.1 Dice molecules Corporation Information
6.26.2 Dice molecules Ankylosing Spondylitis Medication Description and Business Overview
6.26.3 Dice molecules Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.26.4 Dice molecules Ankylosing Spondylitis Medication Product Portfolio
6.26.5 Dice molecules Recent Developments/Updates
7 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS
7.1 Ankylosing Spondylitis Medication Industry Chain Analysis
7.2 Ankylosing Spondylitis Medication Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Ankylosing Spondylitis Medication Production Mode & Process
7.4 Ankylosing Spondylitis Medication Sales and Marketing
7.4.1 Ankylosing Spondylitis Medication Sales Channels
7.4.2 Ankylosing Spondylitis Medication Distributors
7.5 Ankylosing Spondylitis Medication Customers
8 ANKYLOSING SPONDYLITIS MEDICATION MARKET DYNAMICS
8.1 Ankylosing Spondylitis Medication Industry Trends
8.2 Ankylosing Spondylitis Medication Market Drivers
8.3 Ankylosing Spondylitis Medication Market Challenges
8.4 Ankylosing Spondylitis Medication Market Restraints
9 RESEARCH FINDING AND CONCLUSION
10 METHODOLOGY AND DATA SOURCE
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Overview and Scope of Ankylosing Spondylitis Medication
1.2 Ankylosing Spondylitis Medication Segment by Type
1.2.1 Global Ankylosing Spondylitis Medication Market Value Comparison by Type (2023-2029)
1.2.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
1.2.3 Corticosteroids
1.2.4 Disease-Modifying Antirheumatic Drugs (DMARDs)
1.2.5 Biologics (TNF-blocking Agents)
1.2.6 Sulfasalazine
1.2.7 Methotrexate
1.2.8 Others
1.3 Ankylosing Spondylitis Medication Segment by Application
1.3.1 Global Ankylosing Spondylitis Medication Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Specialist Clinic
1.4 Global Ankylosing Spondylitis Medication Market Size Estimates and Forecasts
1.4.1 Global Ankylosing Spondylitis Medication Revenue 2018-2029
1.4.2 Global Ankylosing Spondylitis Medication Sales 2018-2029
1.4.3 Global Ankylosing Spondylitis Medication Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 ANKYLOSING SPONDYLITIS MEDICATION MARKET COMPETITION BY MANUFACTURERS
2.1 Global Ankylosing Spondylitis Medication Sales Market Share by Manufacturers (2018-2023)
2.2 Global Ankylosing Spondylitis Medication Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Ankylosing Spondylitis Medication Average Price by Manufacturers (2018-2023)
2.4 Global Ankylosing Spondylitis Medication Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Ankylosing Spondylitis Medication, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Ankylosing Spondylitis Medication, Product Type & Application
2.7 Ankylosing Spondylitis Medication Market Competitive Situation and Trends
2.7.1 Ankylosing Spondylitis Medication Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Ankylosing Spondylitis Medication Players Market Share by Revenue
2.7.3 Global Ankylosing Spondylitis Medication Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 ANKYLOSING SPONDYLITIS MEDICATION RETROSPECTIVE MARKET SCENARIO BY REGION
3.1 Global Ankylosing Spondylitis Medication Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Ankylosing Spondylitis Medication Global Ankylosing Spondylitis Medication Sales by Region: 2018-2029
3.2.1 Global Ankylosing Spondylitis Medication Sales by Region: 2018-2023
3.2.2 Global Ankylosing Spondylitis Medication Sales by Region: 2024-2029
3.3 Global Ankylosing Spondylitis Medication Global Ankylosing Spondylitis Medication Revenue by Region: 2018-2029
3.3.1 Global Ankylosing Spondylitis Medication Revenue by Region: 2018-2023
3.3.2 Global Ankylosing Spondylitis Medication Revenue by Region: 2024-2029
3.4 North America Ankylosing Spondylitis Medication Market Facts & Figures by Country
3.4.1 North America Ankylosing Spondylitis Medication Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Ankylosing Spondylitis Medication Sales by Country (2018-2029)
3.4.3 North America Ankylosing Spondylitis Medication Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Ankylosing Spondylitis Medication Market Facts & Figures by Country
3.5.1 Europe Ankylosing Spondylitis Medication Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Ankylosing Spondylitis Medication Sales by Country (2018-2029)
3.5.3 Europe Ankylosing Spondylitis Medication Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Ankylosing Spondylitis Medication Market Facts & Figures by Country
3.6.1 Asia Pacific Ankylosing Spondylitis Medication Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Ankylosing Spondylitis Medication Sales by Country (2018-2029)
3.6.3 Asia Pacific Ankylosing Spondylitis Medication Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Ankylosing Spondylitis Medication Market Facts & Figures by Country
3.7.1 Latin America Ankylosing Spondylitis Medication Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Ankylosing Spondylitis Medication Sales by Country (2018-2029)
3.7.3 Latin America Ankylosing Spondylitis Medication Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Ankylosing Spondylitis Medication Market Facts & Figures by Country
3.8.1 Middle East and Africa Ankylosing Spondylitis Medication Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Ankylosing Spondylitis Medication Sales by Country (2018-2029)
3.8.3 Middle East and Africa Ankylosing Spondylitis Medication Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 SEGMENT BY TYPE
4.1 Global Ankylosing Spondylitis Medication Sales by Type (2018-2029)
4.1.1 Global Ankylosing Spondylitis Medication Sales by Type (2018-2023)
4.1.2 Global Ankylosing Spondylitis Medication Sales by Type (2024-2029)
4.1.3 Global Ankylosing Spondylitis Medication Sales Market Share by Type (2018-2029)
4.2 Global Ankylosing Spondylitis Medication Revenue by Type (2018-2029)
4.2.1 Global Ankylosing Spondylitis Medication Revenue by Type (2018-2023)
4.2.2 Global Ankylosing Spondylitis Medication Revenue by Type (2024-2029)
4.2.3 Global Ankylosing Spondylitis Medication Revenue Market Share by Type (2018-2029)
4.3 Global Ankylosing Spondylitis Medication Price by Type (2018-2029)
5 SEGMENT BY APPLICATION
5.1 Global Ankylosing Spondylitis Medication Sales by Application (2018-2029)
5.1.1 Global Ankylosing Spondylitis Medication Sales by Application (2018-2023)
5.1.2 Global Ankylosing Spondylitis Medication Sales by Application (2024-2029)
5.1.3 Global Ankylosing Spondylitis Medication Sales Market Share by Application (2018-2029)
5.2 Global Ankylosing Spondylitis Medication Revenue by Application (2018-2029)
5.2.1 Global Ankylosing Spondylitis Medication Revenue by Application (2018-2023)
5.2.2 Global Ankylosing Spondylitis Medication Revenue by Application (2024-2029)
5.2.3 Global Ankylosing Spondylitis Medication Revenue Market Share by Application (2018-2029)
5.3 Global Ankylosing Spondylitis Medication Price by Application (2018-2029)
6 KEY COMPANIES PROFILED
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer Ankylosing Spondylitis Medication Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 UCB Biopharma
6.2.1 UCB Biopharma Corporation Information
6.2.2 UCB Biopharma Description and Business Overview
6.2.3 UCB Biopharma Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.2.4 UCB Biopharma Ankylosing Spondylitis Medication Product Portfolio
6.2.5 UCB Biopharma Recent Developments/Updates
6.3 Hetero Biopharma
6.3.1 Hetero Biopharma Corporation Information
6.3.2 Hetero Biopharma Description and Business Overview
6.3.3 Hetero Biopharma Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Hetero Biopharma Ankylosing Spondylitis Medication Product Portfolio
6.3.5 Hetero Biopharma Recent Developments/Updates
6.4 Amgen
6.4.1 Amgen Corporation Information
6.4.2 Amgen Description and Business Overview
6.4.3 Amgen Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Amgen Ankylosing Spondylitis Medication Product Portfolio
6.4.5 Amgen Recent Developments/Updates
6.5 Cadila Pharmaceuticals
6.5.1 Cadila Pharmaceuticals Corporation Information
6.5.2 Cadila Pharmaceuticals Description and Business Overview
6.5.3 Cadila Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Cadila Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolio
6.5.5 Cadila Pharmaceuticals Recent Developments/Updates
6.6 Torrent Pharmaceuticals
6.6.1 Torrent Pharmaceuticals Corporation Information
6.6.2 Torrent Pharmaceuticals Description and Business Overview
6.6.3 Torrent Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Torrent Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolio
6.6.5 Torrent Pharmaceuticals Recent Developments/Updates
6.7 Cipla
6.6.1 Cipla Corporation Information
6.6.2 Cipla Description and Business Overview
6.6.3 Cipla Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Cipla Ankylosing Spondylitis Medication Product Portfolio
6.7.5 Cipla Recent Developments/Updates
6.8 Emcure Pharmaceuticals
6.8.1 Emcure Pharmaceuticals Corporation Information
6.8.2 Emcure Pharmaceuticals Description and Business Overview
6.8.3 Emcure Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Emcure Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolio
6.8.5 Emcure Pharmaceuticals Recent Developments/Updates
6.9 Boehringer Ingelheim
6.9.1 Boehringer Ingelheim Corporation Information
6.9.2 Boehringer Ingelheim Description and Business Overview
6.9.3 Boehringer Ingelheim Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Boehringer Ingelheim Ankylosing Spondylitis Medication Product Portfolio
6.9.5 Boehringer Ingelheim Recent Developments/Updates
6.10 Zhejiang Hisun Pharmaceuticals
6.10.1 Zhejiang Hisun Pharmaceuticals Corporation Information
6.10.2 Zhejiang Hisun Pharmaceuticals Description and Business Overview
6.10.3 Zhejiang Hisun Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Zhejiang Hisun Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolio
6.10.5 Zhejiang Hisun Pharmaceuticals Recent Developments/Updates
6.11 Biocad
6.11.1 Biocad Corporation Information
6.11.2 Biocad Ankylosing Spondylitis Medication Description and Business Overview
6.11.3 Biocad Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Biocad Ankylosing Spondylitis Medication Product Portfolio
6.11.5 Biocad Recent Developments/Updates
6.12 AbbVie
6.12.1 AbbVie Corporation Information
6.12.2 AbbVie Ankylosing Spondylitis Medication Description and Business Overview
6.12.3 AbbVie Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.12.4 AbbVie Ankylosing Spondylitis Medication Product Portfolio
6.12.5 AbbVie Recent Developments/Updates
6.13 Mycenax Biotech
6.13.1 Mycenax Biotech Corporation Information
6.13.2 Mycenax Biotech Ankylosing Spondylitis Medication Description and Business Overview
6.13.3 Mycenax Biotech Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Mycenax Biotech Ankylosing Spondylitis Medication Product Portfolio
6.13.5 Mycenax Biotech Recent Developments/Updates
6.14 Celltrion
6.14.1 Celltrion Corporation Information
6.14.2 Celltrion Ankylosing Spondylitis Medication Description and Business Overview
6.14.3 Celltrion Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Celltrion Ankylosing Spondylitis Medication Product Portfolio
6.14.5 Celltrion Recent Developments/Updates
6.15 Gilead Sciences
6.15.1 Gilead Sciences Corporation Information
6.15.2 Gilead Sciences Ankylosing Spondylitis Medication Description and Business Overview
6.15.3 Gilead Sciences Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Gilead Sciences Ankylosing Spondylitis Medication Product Portfolio
6.15.5 Gilead Sciences Recent Developments/Updates
6.16 Jiangsu HengRui Medicine Co., Ltd.
6.16.1 Jiangsu HengRui Medicine Co., Ltd. Corporation Information
6.16.2 Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Description and Business Overview
6.16.3 Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Product Portfolio
6.16.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
6.17 Izana Bioscience
6.17.1 Izana Bioscience Corporation Information
6.17.2 Izana Bioscience Ankylosing Spondylitis Medication Description and Business Overview
6.17.3 Izana Bioscience Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Izana Bioscience Ankylosing Spondylitis Medication Product Portfolio
6.17.5 Izana Bioscience Recent Developments/Updates
6.18 Suzhou Zelgen Biopharmaceuticals
6.18.1 Suzhou Zelgen Biopharmaceuticals Corporation Information
6.18.2 Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Description and Business Overview
6.18.3 Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Product Portfolio
6.18.5 Suzhou Zelgen Biopharmaceuticals Recent Developments/Updates
6.19 Iltoo Pharma
6.19.1 Iltoo Pharma Corporation Information
6.19.2 Iltoo Pharma Ankylosing Spondylitis Medication Description and Business Overview
6.19.3 Iltoo Pharma Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Iltoo Pharma Ankylosing Spondylitis Medication Product Portfolio
6.19.5 Iltoo Pharma Recent Developments/Updates
6.20 Kinevant Sciences
6.20.1 Kinevant Sciences Corporation Information
6.20.2 Kinevant Sciences Ankylosing Spondylitis Medication Description and Business Overview
6.20.3 Kinevant Sciences Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Kinevant Sciences Ankylosing Spondylitis Medication Product Portfolio
6.20.5 Kinevant Sciences Recent Developments/Updates
6.21 Qyuns Therapeutics
6.21.1 Qyuns Therapeutics Corporation Information
6.21.2 Qyuns Therapeutics Ankylosing Spondylitis Medication Description and Business Overview
6.21.3 Qyuns Therapeutics Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Qyuns Therapeutics Ankylosing Spondylitis Medication Product Portfolio
6.21.5 Qyuns Therapeutics Recent Developments/Updates
6.22 Akeso Biopharma
6.22.1 Akeso Biopharma Corporation Information
6.22.2 Akeso Biopharma Ankylosing Spondylitis Medication Description and Business Overview
6.22.3 Akeso Biopharma Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.22.4 Akeso Biopharma Ankylosing Spondylitis Medication Product Portfolio
6.22.5 Akeso Biopharma Recent Developments/Updates
6.23 Nimbus Therapeutics
6.23.1 Nimbus Therapeutics Corporation Information
6.23.2 Nimbus Therapeutics Ankylosing Spondylitis Medication Description and Business Overview
6.23.3 Nimbus Therapeutics Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Nimbus Therapeutics Ankylosing Spondylitis Medication Product Portfolio
6.23.5 Nimbus Therapeutics Recent Developments/Updates
6.24 Enzene Biosciences
6.24.1 Enzene Biosciences Corporation Information
6.24.2 Enzene Biosciences Ankylosing Spondylitis Medication Description and Business Overview
6.24.3 Enzene Biosciences Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.24.4 Enzene Biosciences Ankylosing Spondylitis Medication Product Portfolio
6.24.5 Enzene Biosciences Recent Developments/Updates
6.25 Xbrane Biopharma
6.25.1 Xbrane Biopharma Corporation Information
6.25.2 Xbrane Biopharma Ankylosing Spondylitis Medication Description and Business Overview
6.25.3 Xbrane Biopharma Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.25.4 Xbrane Biopharma Ankylosing Spondylitis Medication Product Portfolio
6.25.5 Xbrane Biopharma Recent Developments/Updates
6.26 Dice molecules
6.26.1 Dice molecules Corporation Information
6.26.2 Dice molecules Ankylosing Spondylitis Medication Description and Business Overview
6.26.3 Dice molecules Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2018-2023)
6.26.4 Dice molecules Ankylosing Spondylitis Medication Product Portfolio
6.26.5 Dice molecules Recent Developments/Updates
7 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS
7.1 Ankylosing Spondylitis Medication Industry Chain Analysis
7.2 Ankylosing Spondylitis Medication Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Ankylosing Spondylitis Medication Production Mode & Process
7.4 Ankylosing Spondylitis Medication Sales and Marketing
7.4.1 Ankylosing Spondylitis Medication Sales Channels
7.4.2 Ankylosing Spondylitis Medication Distributors
7.5 Ankylosing Spondylitis Medication Customers
8 ANKYLOSING SPONDYLITIS MEDICATION MARKET DYNAMICS
8.1 Ankylosing Spondylitis Medication Industry Trends
8.2 Ankylosing Spondylitis Medication Market Drivers
8.3 Ankylosing Spondylitis Medication Market Challenges
8.4 Ankylosing Spondylitis Medication Market Restraints
9 RESEARCH FINDING AND CONCLUSION
10 METHODOLOGY AND DATA SOURCE
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
LIST OF TABLES
Table 1. Global Ankylosing Spondylitis Medication Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Ankylosing Spondylitis Medication Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Ankylosing Spondylitis Medication Market Competitive Situation by Manufacturers in 2022
Table 4. Global Ankylosing Spondylitis Medication Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Ankylosing Spondylitis Medication Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Ankylosing Spondylitis Medication Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Ankylosing Spondylitis Medication Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Ankylosing Spondylitis Medication Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Ankylosing Spondylitis Medication, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Ankylosing Spondylitis Medication, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Ankylosing Spondylitis Medication, Product Type & Application
Table 12. Global Key Manufacturers of Ankylosing Spondylitis Medication, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Ankylosing Spondylitis Medication by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ankylosing Spondylitis Medication as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Ankylosing Spondylitis Medication Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Ankylosing Spondylitis Medication Sales by Region (2018-2023) & (K Units)
Table 18. Global Ankylosing Spondylitis Medication Sales Market Share by Region (2018-2023)
Table 19. Global Ankylosing Spondylitis Medication Sales by Region (2024-2029) & (K Units)
Table 20. Global Ankylosing Spondylitis Medication Sales Market Share by Region (2024-2029)
Table 21. Global Ankylosing Spondylitis Medication Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Ankylosing Spondylitis Medication Revenue Market Share by Region (2018-2023)
Table 23. Global Ankylosing Spondylitis Medication Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Ankylosing Spondylitis Medication Revenue Market Share by Region (2024-2029)
Table 25. North America Ankylosing Spondylitis Medication Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Ankylosing Spondylitis Medication Sales by Country (2018-2023) & (K Units)
Table 27. North America Ankylosing Spondylitis Medication Sales by Country (2024-2029) & (K Units)
Table 28. North America Ankylosing Spondylitis Medication Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Ankylosing Spondylitis Medication Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Ankylosing Spondylitis Medication Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Ankylosing Spondylitis Medication Sales by Country (2018-2023) & (K Units)
Table 32. Europe Ankylosing Spondylitis Medication Sales by Country (2024-2029) & (K Units)
Table 33. Europe Ankylosing Spondylitis Medication Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Ankylosing Spondylitis Medication Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Ankylosing Spondylitis Medication Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Ankylosing Spondylitis Medication Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Ankylosing Spondylitis Medication Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Ankylosing Spondylitis Medication Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Ankylosing Spondylitis Medication Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Ankylosing Spondylitis Medication Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Ankylosing Spondylitis Medication Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Ankylosing Spondylitis Medication Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Ankylosing Spondylitis Medication Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Ankylosing Spondylitis Medication Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Ankylosing Spondylitis Medication Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Ankylosing Spondylitis Medication Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Ankylosing Spondylitis Medication Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Ankylosing Spondylitis Medication Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Ankylosing Spondylitis Medication Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Ankylosing Spondylitis Medication Sales (K Units) by Type (2018-2023)
Table 51. Global Ankylosing Spondylitis Medication Sales (K Units) by Type (2024-2029)
Table 52. Global Ankylosing Spondylitis Medication Sales Market Share by Type (2018-2023)
Table 53. Global Ankylosing Spondylitis Medication Sales Market Share by Type (2024-2029)
Table 54. Global Ankylosing Spondylitis Medication Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Ankylosing Spondylitis Medication Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Ankylosing Spondylitis Medication Revenue Market Share by Type (2018-2023)
Table 57. Global Ankylosing Spondylitis Medication Revenue Market Share by Type (2024-2029)
Table 58. Global Ankylosing Spondylitis Medication Price (US$/Unit) by Type (2018-2023)
Table 59. Global Ankylosing Spondylitis Medication Price (US$/Unit) by Type (2024-2029)
Table 60. Global Ankylosing Spondylitis Medication Sales (K Units) by Application (2018-2023)
Table 61. Global Ankylosing Spondylitis Medication Sales (K Units) by Application (2024-2029)
Table 62. Global Ankylosing Spondylitis Medication Sales Market Share by Application (2018-2023)
Table 63. Global Ankylosing Spondylitis Medication Sales Market Share by Application (2024-2029)
Table 64. Global Ankylosing Spondylitis Medication Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Ankylosing Spondylitis Medication Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Ankylosing Spondylitis Medication Revenue Market Share by Application (2018-2023)
Table 67. Global Ankylosing Spondylitis Medication Revenue Market Share by Application (2024-2029)
Table 68. Global Ankylosing Spondylitis Medication Price (US$/Unit) by Application (2018-2023)
Table 69. Global Ankylosing Spondylitis Medication Price (US$/Unit) by Application (2024-2029)
Table 70. Pfizer Corporation Information
Table 71. Pfizer Description and Business Overview
Table 72. Pfizer Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Pfizer Ankylosing Spondylitis Medication Product
Table 74. Pfizer Recent Developments/Updates
Table 75. UCB Biopharma Corporation Information
Table 76. UCB Biopharma Description and Business Overview
Table 77. UCB Biopharma Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. UCB Biopharma Ankylosing Spondylitis Medication Product
Table 79. UCB Biopharma Recent Developments/Updates
Table 80. Hetero Biopharma Corporation Information
Table 81. Hetero Biopharma Description and Business Overview
Table 82. Hetero Biopharma Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Hetero Biopharma Ankylosing Spondylitis Medication Product
Table 84. Hetero Biopharma Recent Developments/Updates
Table 85. Amgen Corporation Information
Table 86. Amgen Description and Business Overview
Table 87. Amgen Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Amgen Ankylosing Spondylitis Medication Product
Table 89. Amgen Recent Developments/Updates
Table 90. Cadila Pharmaceuticals Corporation Information
Table 91. Cadila Pharmaceuticals Description and Business Overview
Table 92. Cadila Pharmaceuticals Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Cadila Pharmaceuticals Ankylosing Spondylitis Medication Product
Table 94. Cadila Pharmaceuticals Recent Developments/Updates
Table 95. Torrent Pharmaceuticals Corporation Information
Table 96. Torrent Pharmaceuticals Description and Business Overview
Table 97. Torrent Pharmaceuticals Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Torrent Pharmaceuticals Ankylosing Spondylitis Medication Product
Table 99. Torrent Pharmaceuticals Recent Developments/Updates
Table 100. Cipla Corporation Information
Table 101. Cipla Description and Business Overview
Table 102. Cipla Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Cipla Ankylosing Spondylitis Medication Product
Table 104. Cipla Recent Developments/Updates
Table 105. Emcure Pharmaceuticals Corporation Information
Table 106. Emcure Pharmaceuticals Description and Business Overview
Table 107. Emcure Pharmaceuticals Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Emcure Pharmaceuticals Ankylosing Spondylitis Medication Product
Table 109. Emcure Pharmaceuticals Recent Developments/Updates
Table 110. Boehringer Ingelheim Corporation Information
Table 111. Boehringer Ingelheim Description and Business Overview
Table 112. Boehringer Ingelheim Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Boehringer Ingelheim Ankylosing Spondylitis Medication Product
Table 114. Boehringer Ingelheim Recent Developments/Updates
Table 115. Zhejiang Hisun Pharmaceuticals Corporation Information
Table 116. Zhejiang Hisun Pharmaceuticals Description and Business Overview
Table 117. Zhejiang Hisun Pharmaceuticals Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Zhejiang Hisun Pharmaceuticals Ankylosing Spondylitis Medication Product
Table 119. Zhejiang Hisun Pharmaceuticals Recent Developments/Updates
Table 120. Biocad Corporation Information
Table 121. Biocad Description and Business Overview
Table 122. Biocad Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Biocad Ankylosing Spondylitis Medication Product
Table 124. Biocad Recent Developments/Updates
Table 125. AbbVie Corporation Information
Table 126. AbbVie Description and Business Overview
Table 127. AbbVie Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. AbbVie Ankylosing Spondylitis Medication Product
Table 129. AbbVie Recent Developments/Updates
Table 130. Mycenax Biotech Corporation Information
Table 131. Mycenax Biotech Description and Business Overview
Table 132. Mycenax Biotech Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Mycenax Biotech Ankylosing Spondylitis Medication Product
Table 134. Mycenax Biotech Recent Developments/Updates
Table 135. Celltrion Corporation Information
Table 136. Celltrion Description and Business Overview
Table 137. Celltrion Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Celltrion Ankylosing Spondylitis Medication Product
Table 139. Celltrion Recent Developments/Updates
Table 140. Gilead Sciences Corporation Information
Table 141. Gilead Sciences Description and Business Overview
Table 142. Gilead Sciences Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 143. Gilead Sciences Ankylosing Spondylitis Medication Product
Table 144. Gilead Sciences Recent Developments/Updates
Table 145. Jiangsu HengRui Medicine Co., Ltd. Corporation Information
Table 146. Jiangsu HengRui Medicine Co., Ltd. Description and Business Overview
Table 147. Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 148. Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Product
Table 149. Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
Table 150. Izana Bioscience Corporation Information
Table 151. Izana Bioscience Description and Business Overview
Table 152. Izana Bioscience Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 153. Izana Bioscience Ankylosing Spondylitis Medication Product
Table 154. Izana Bioscience Recent Developments/Updates
Table 155. Suzhou Zelgen Biopharmaceuticals Corporation Information
Table 156. Suzhou Zelgen Biopharmaceuticals Description and Business Overview
Table 157. Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 158. Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Product
Table 159. Suzhou Zelgen Biopharmaceuticals Recent Developments/Updates
Table 160. Iltoo Pharma Corporation Information
Table 161. Iltoo Pharma Description and Business Overview
Table 162. Iltoo Pharma Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 163. Iltoo Pharma Ankylosing Spondylitis Medication Product
Table 164. Iltoo Pharma Recent Developments/Updates
Table 165. Kinevant Sciences Corporation Information
Table 166. Kinevant Sciences Description and Business Overview
Table 167. Kinevant Sciences Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 168. Kinevant Sciences Ankylosing Spondylitis Medication Product
Table 169. Kinevant Sciences Recent Developments/Updates
Table 170. Qyuns Therapeutics Corporation Information
Table 171. Qyuns Therapeutics Description and Business Overview
Table 172. Qyuns Therapeutics Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 173. Qyuns Therapeutics Ankylosing Spondylitis Medication Product
Table 174. Qyuns Therapeutics Recent Developments/Updates
Table 175. Akeso Biopharma Corporation Information
Table 176. Akeso Biopharma Description and Business Overview
Table 177. Akeso Biopharma Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 178. Akeso Biopharma Ankylosing Spondylitis Medication Product
Table 179. Akeso Biopharma Recent Developments/Updates
Table 180. Nimbus Therapeutics Corporation Information
Table 181. Nimbus Therapeutics Description and Business Overview
Table 182. Nimbus Therapeutics Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 183. Nimbus Therapeutics Ankylosing Spondylitis Medication Product
Table 184. Nimbus Therapeutics Recent Developments/Updates
Table 185. Enzene Biosciences Corporation Information
Table 186. Enzene Biosciences Description and Business Overview
Table 187. Enzene Biosciences Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 188. Enzene Biosciences Ankylosing Spondylitis Medication Product
Table 189. Enzene Biosciences Recent Developments/Updates
Table 190. Xbrane Biopharma Corporation Information
Table 191. Xbrane Biopharma Description and Business Overview
Table 192. Xbrane Biopharma Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 193. Xbrane Biopharma Ankylosing Spondylitis Medication Product
Table 194. Xbrane Biopharma Recent Developments/Updates
Table 195. Dice molecules Corporation Information
Table 196. Dice molecules Description and Business Overview
Table 197. Dice molecules Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 198. Dice molecules Ankylosing Spondylitis Medication Product
Table 199. Dice molecules Recent Developments/Updates
Table 200. Key Raw Materials Lists
Table 201. Raw Materials Key Suppliers Lists
Table 202. Ankylosing Spondylitis Medication Distributors List
Table 203. Ankylosing Spondylitis Medication Customers List
Table 204. Ankylosing Spondylitis Medication Market Trends
Table 205. Ankylosing Spondylitis Medication Market Drivers
Table 206. Ankylosing Spondylitis Medication Market Challenges
Table 207. Ankylosing Spondylitis Medication Market Restraints
Table 208. Research Programs/Design for This Report
Table 209. Key Data Information from Secondary Sources
Table 210. Key Data Information from Primary Sources
Table 1. Global Ankylosing Spondylitis Medication Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Ankylosing Spondylitis Medication Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Ankylosing Spondylitis Medication Market Competitive Situation by Manufacturers in 2022
Table 4. Global Ankylosing Spondylitis Medication Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Ankylosing Spondylitis Medication Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Ankylosing Spondylitis Medication Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Ankylosing Spondylitis Medication Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Ankylosing Spondylitis Medication Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Ankylosing Spondylitis Medication, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Ankylosing Spondylitis Medication, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Ankylosing Spondylitis Medication, Product Type & Application
Table 12. Global Key Manufacturers of Ankylosing Spondylitis Medication, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Ankylosing Spondylitis Medication by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ankylosing Spondylitis Medication as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Ankylosing Spondylitis Medication Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Ankylosing Spondylitis Medication Sales by Region (2018-2023) & (K Units)
Table 18. Global Ankylosing Spondylitis Medication Sales Market Share by Region (2018-2023)
Table 19. Global Ankylosing Spondylitis Medication Sales by Region (2024-2029) & (K Units)
Table 20. Global Ankylosing Spondylitis Medication Sales Market Share by Region (2024-2029)
Table 21. Global Ankylosing Spondylitis Medication Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Ankylosing Spondylitis Medication Revenue Market Share by Region (2018-2023)
Table 23. Global Ankylosing Spondylitis Medication Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Ankylosing Spondylitis Medication Revenue Market Share by Region (2024-2029)
Table 25. North America Ankylosing Spondylitis Medication Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Ankylosing Spondylitis Medication Sales by Country (2018-2023) & (K Units)
Table 27. North America Ankylosing Spondylitis Medication Sales by Country (2024-2029) & (K Units)
Table 28. North America Ankylosing Spondylitis Medication Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Ankylosing Spondylitis Medication Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Ankylosing Spondylitis Medication Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Ankylosing Spondylitis Medication Sales by Country (2018-2023) & (K Units)
Table 32. Europe Ankylosing Spondylitis Medication Sales by Country (2024-2029) & (K Units)
Table 33. Europe Ankylosing Spondylitis Medication Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Ankylosing Spondylitis Medication Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Ankylosing Spondylitis Medication Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Ankylosing Spondylitis Medication Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Ankylosing Spondylitis Medication Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Ankylosing Spondylitis Medication Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Ankylosing Spondylitis Medication Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Ankylosing Spondylitis Medication Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Ankylosing Spondylitis Medication Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Ankylosing Spondylitis Medication Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Ankylosing Spondylitis Medication Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Ankylosing Spondylitis Medication Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Ankylosing Spondylitis Medication Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Ankylosing Spondylitis Medication Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Ankylosing Spondylitis Medication Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Ankylosing Spondylitis Medication Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Ankylosing Spondylitis Medication Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Ankylosing Spondylitis Medication Sales (K Units) by Type (2018-2023)
Table 51. Global Ankylosing Spondylitis Medication Sales (K Units) by Type (2024-2029)
Table 52. Global Ankylosing Spondylitis Medication Sales Market Share by Type (2018-2023)
Table 53. Global Ankylosing Spondylitis Medication Sales Market Share by Type (2024-2029)
Table 54. Global Ankylosing Spondylitis Medication Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Ankylosing Spondylitis Medication Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Ankylosing Spondylitis Medication Revenue Market Share by Type (2018-2023)
Table 57. Global Ankylosing Spondylitis Medication Revenue Market Share by Type (2024-2029)
Table 58. Global Ankylosing Spondylitis Medication Price (US$/Unit) by Type (2018-2023)
Table 59. Global Ankylosing Spondylitis Medication Price (US$/Unit) by Type (2024-2029)
Table 60. Global Ankylosing Spondylitis Medication Sales (K Units) by Application (2018-2023)
Table 61. Global Ankylosing Spondylitis Medication Sales (K Units) by Application (2024-2029)
Table 62. Global Ankylosing Spondylitis Medication Sales Market Share by Application (2018-2023)
Table 63. Global Ankylosing Spondylitis Medication Sales Market Share by Application (2024-2029)
Table 64. Global Ankylosing Spondylitis Medication Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Ankylosing Spondylitis Medication Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Ankylosing Spondylitis Medication Revenue Market Share by Application (2018-2023)
Table 67. Global Ankylosing Spondylitis Medication Revenue Market Share by Application (2024-2029)
Table 68. Global Ankylosing Spondylitis Medication Price (US$/Unit) by Application (2018-2023)
Table 69. Global Ankylosing Spondylitis Medication Price (US$/Unit) by Application (2024-2029)
Table 70. Pfizer Corporation Information
Table 71. Pfizer Description and Business Overview
Table 72. Pfizer Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Pfizer Ankylosing Spondylitis Medication Product
Table 74. Pfizer Recent Developments/Updates
Table 75. UCB Biopharma Corporation Information
Table 76. UCB Biopharma Description and Business Overview
Table 77. UCB Biopharma Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. UCB Biopharma Ankylosing Spondylitis Medication Product
Table 79. UCB Biopharma Recent Developments/Updates
Table 80. Hetero Biopharma Corporation Information
Table 81. Hetero Biopharma Description and Business Overview
Table 82. Hetero Biopharma Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Hetero Biopharma Ankylosing Spondylitis Medication Product
Table 84. Hetero Biopharma Recent Developments/Updates
Table 85. Amgen Corporation Information
Table 86. Amgen Description and Business Overview
Table 87. Amgen Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Amgen Ankylosing Spondylitis Medication Product
Table 89. Amgen Recent Developments/Updates
Table 90. Cadila Pharmaceuticals Corporation Information
Table 91. Cadila Pharmaceuticals Description and Business Overview
Table 92. Cadila Pharmaceuticals Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Cadila Pharmaceuticals Ankylosing Spondylitis Medication Product
Table 94. Cadila Pharmaceuticals Recent Developments/Updates
Table 95. Torrent Pharmaceuticals Corporation Information
Table 96. Torrent Pharmaceuticals Description and Business Overview
Table 97. Torrent Pharmaceuticals Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Torrent Pharmaceuticals Ankylosing Spondylitis Medication Product
Table 99. Torrent Pharmaceuticals Recent Developments/Updates
Table 100. Cipla Corporation Information
Table 101. Cipla Description and Business Overview
Table 102. Cipla Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Cipla Ankylosing Spondylitis Medication Product
Table 104. Cipla Recent Developments/Updates
Table 105. Emcure Pharmaceuticals Corporation Information
Table 106. Emcure Pharmaceuticals Description and Business Overview
Table 107. Emcure Pharmaceuticals Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Emcure Pharmaceuticals Ankylosing Spondylitis Medication Product
Table 109. Emcure Pharmaceuticals Recent Developments/Updates
Table 110. Boehringer Ingelheim Corporation Information
Table 111. Boehringer Ingelheim Description and Business Overview
Table 112. Boehringer Ingelheim Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Boehringer Ingelheim Ankylosing Spondylitis Medication Product
Table 114. Boehringer Ingelheim Recent Developments/Updates
Table 115. Zhejiang Hisun Pharmaceuticals Corporation Information
Table 116. Zhejiang Hisun Pharmaceuticals Description and Business Overview
Table 117. Zhejiang Hisun Pharmaceuticals Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Zhejiang Hisun Pharmaceuticals Ankylosing Spondylitis Medication Product
Table 119. Zhejiang Hisun Pharmaceuticals Recent Developments/Updates
Table 120. Biocad Corporation Information
Table 121. Biocad Description and Business Overview
Table 122. Biocad Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Biocad Ankylosing Spondylitis Medication Product
Table 124. Biocad Recent Developments/Updates
Table 125. AbbVie Corporation Information
Table 126. AbbVie Description and Business Overview
Table 127. AbbVie Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. AbbVie Ankylosing Spondylitis Medication Product
Table 129. AbbVie Recent Developments/Updates
Table 130. Mycenax Biotech Corporation Information
Table 131. Mycenax Biotech Description and Business Overview
Table 132. Mycenax Biotech Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Mycenax Biotech Ankylosing Spondylitis Medication Product
Table 134. Mycenax Biotech Recent Developments/Updates
Table 135. Celltrion Corporation Information
Table 136. Celltrion Description and Business Overview
Table 137. Celltrion Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Celltrion Ankylosing Spondylitis Medication Product
Table 139. Celltrion Recent Developments/Updates
Table 140. Gilead Sciences Corporation Information
Table 141. Gilead Sciences Description and Business Overview
Table 142. Gilead Sciences Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 143. Gilead Sciences Ankylosing Spondylitis Medication Product
Table 144. Gilead Sciences Recent Developments/Updates
Table 145. Jiangsu HengRui Medicine Co., Ltd. Corporation Information
Table 146. Jiangsu HengRui Medicine Co., Ltd. Description and Business Overview
Table 147. Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 148. Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Product
Table 149. Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
Table 150. Izana Bioscience Corporation Information
Table 151. Izana Bioscience Description and Business Overview
Table 152. Izana Bioscience Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 153. Izana Bioscience Ankylosing Spondylitis Medication Product
Table 154. Izana Bioscience Recent Developments/Updates
Table 155. Suzhou Zelgen Biopharmaceuticals Corporation Information
Table 156. Suzhou Zelgen Biopharmaceuticals Description and Business Overview
Table 157. Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 158. Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Product
Table 159. Suzhou Zelgen Biopharmaceuticals Recent Developments/Updates
Table 160. Iltoo Pharma Corporation Information
Table 161. Iltoo Pharma Description and Business Overview
Table 162. Iltoo Pharma Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 163. Iltoo Pharma Ankylosing Spondylitis Medication Product
Table 164. Iltoo Pharma Recent Developments/Updates
Table 165. Kinevant Sciences Corporation Information
Table 166. Kinevant Sciences Description and Business Overview
Table 167. Kinevant Sciences Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 168. Kinevant Sciences Ankylosing Spondylitis Medication Product
Table 169. Kinevant Sciences Recent Developments/Updates
Table 170. Qyuns Therapeutics Corporation Information
Table 171. Qyuns Therapeutics Description and Business Overview
Table 172. Qyuns Therapeutics Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 173. Qyuns Therapeutics Ankylosing Spondylitis Medication Product
Table 174. Qyuns Therapeutics Recent Developments/Updates
Table 175. Akeso Biopharma Corporation Information
Table 176. Akeso Biopharma Description and Business Overview
Table 177. Akeso Biopharma Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 178. Akeso Biopharma Ankylosing Spondylitis Medication Product
Table 179. Akeso Biopharma Recent Developments/Updates
Table 180. Nimbus Therapeutics Corporation Information
Table 181. Nimbus Therapeutics Description and Business Overview
Table 182. Nimbus Therapeutics Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 183. Nimbus Therapeutics Ankylosing Spondylitis Medication Product
Table 184. Nimbus Therapeutics Recent Developments/Updates
Table 185. Enzene Biosciences Corporation Information
Table 186. Enzene Biosciences Description and Business Overview
Table 187. Enzene Biosciences Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 188. Enzene Biosciences Ankylosing Spondylitis Medication Product
Table 189. Enzene Biosciences Recent Developments/Updates
Table 190. Xbrane Biopharma Corporation Information
Table 191. Xbrane Biopharma Description and Business Overview
Table 192. Xbrane Biopharma Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 193. Xbrane Biopharma Ankylosing Spondylitis Medication Product
Table 194. Xbrane Biopharma Recent Developments/Updates
Table 195. Dice molecules Corporation Information
Table 196. Dice molecules Description and Business Overview
Table 197. Dice molecules Ankylosing Spondylitis Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 198. Dice molecules Ankylosing Spondylitis Medication Product
Table 199. Dice molecules Recent Developments/Updates
Table 200. Key Raw Materials Lists
Table 201. Raw Materials Key Suppliers Lists
Table 202. Ankylosing Spondylitis Medication Distributors List
Table 203. Ankylosing Spondylitis Medication Customers List
Table 204. Ankylosing Spondylitis Medication Market Trends
Table 205. Ankylosing Spondylitis Medication Market Drivers
Table 206. Ankylosing Spondylitis Medication Market Challenges
Table 207. Ankylosing Spondylitis Medication Market Restraints
Table 208. Research Programs/Design for This Report
Table 209. Key Data Information from Secondary Sources
Table 210. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Product Picture of Ankylosing Spondylitis Medication
Figure 2. Global Ankylosing Spondylitis Medication Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Ankylosing Spondylitis Medication Market Share by Type in 2022 & 2029
Figure 4. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Product Picture
Figure 5. Corticosteroids Product Picture
Figure 6. Disease-Modifying Antirheumatic Drugs (DMARDs) Product Picture
Figure 7. Biologics (TNF-blocking Agents) Product Picture
Figure 8. Sulfasalazine Product Picture
Figure 9. Methotrexate Product Picture
Figure 10. Others Product Picture
Figure 11. Global Ankylosing Spondylitis Medication Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 12. Global Ankylosing Spondylitis Medication Market Share by Application in 2022 & 2029
Figure 13. Hospital
Figure 14. Specialist Clinic
Figure 15. Global Ankylosing Spondylitis Medication Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Ankylosing Spondylitis Medication Market Size (2018-2029) & (US$ Million)
Figure 17. Global Ankylosing Spondylitis Medication Sales (2018-2029) & (K Units)
Figure 18. Global Ankylosing Spondylitis Medication Average Price (US$/Unit) & (2018-2029)
Figure 19. Ankylosing Spondylitis Medication Report Years Considered
Figure 20. Ankylosing Spondylitis Medication Sales Share by Manufacturers in 2022
Figure 21. Global Ankylosing Spondylitis Medication Revenue Share by Manufacturers in 2022
Figure 22. The Global 5 and 10 Largest Ankylosing Spondylitis Medication Players: Market Share by Revenue in 2022
Figure 23. Ankylosing Spondylitis Medication Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 24. Global Ankylosing Spondylitis Medication Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 25. North America Ankylosing Spondylitis Medication Sales Market Share by Country (2018-2029)
Figure 26. North America Ankylosing Spondylitis Medication Revenue Market Share by Country (2018-2029)
Figure 27. United States Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. Canada Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. Europe Ankylosing Spondylitis Medication Sales Market Share by Country (2018-2029)
Figure 30. Europe Ankylosing Spondylitis Medication Revenue Market Share by Country (2018-2029)
Figure 31. Germany Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. France Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. U.K. Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Italy Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Russia Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Asia Pacific Ankylosing Spondylitis Medication Sales Market Share by Region (2018-2029)
Figure 37. Asia Pacific Ankylosing Spondylitis Medication Revenue Market Share by Region (2018-2029)
Figure 38. China Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Japan Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. South Korea Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. India Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Australia Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. China Taiwan Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Southeast Asia Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Latin America Ankylosing Spondylitis Medication Sales Market Share by Country (2018-2029)
Figure 46. Latin America Ankylosing Spondylitis Medication Revenue Market Share by Country (2018-2029)
Figure 47. Mexico Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Brazil Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Argentina Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Middle East & Africa Ankylosing Spondylitis Medication Sales Market Share by Country (2018-2029)
Figure 51. Middle East & Africa Ankylosing Spondylitis Medication Revenue Market Share by Country (2018-2029)
Figure 52. Turkey Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Saudi Arabia Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. UAE Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. Global Sales Market Share of Ankylosing Spondylitis Medication by Type (2018-2029)
Figure 56. Global Revenue Market Share of Ankylosing Spondylitis Medication by Type (2018-2029)
Figure 57. Global Ankylosing Spondylitis Medication Price (US$/Unit) by Type (2018-2029)
Figure 58. Global Sales Market Share of Ankylosing Spondylitis Medication by Application (2018-2029)
Figure 59. Global Revenue Market Share of Ankylosing Spondylitis Medication by Application (2018-2029)
Figure 60. Global Ankylosing Spondylitis Medication Price (US$/Unit) by Application (2018-2029)
Figure 61. Ankylosing Spondylitis Medication Value Chain
Figure 62. Ankylosing Spondylitis Medication Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Figure 1. Product Picture of Ankylosing Spondylitis Medication
Figure 2. Global Ankylosing Spondylitis Medication Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Ankylosing Spondylitis Medication Market Share by Type in 2022 & 2029
Figure 4. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Product Picture
Figure 5. Corticosteroids Product Picture
Figure 6. Disease-Modifying Antirheumatic Drugs (DMARDs) Product Picture
Figure 7. Biologics (TNF-blocking Agents) Product Picture
Figure 8. Sulfasalazine Product Picture
Figure 9. Methotrexate Product Picture
Figure 10. Others Product Picture
Figure 11. Global Ankylosing Spondylitis Medication Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 12. Global Ankylosing Spondylitis Medication Market Share by Application in 2022 & 2029
Figure 13. Hospital
Figure 14. Specialist Clinic
Figure 15. Global Ankylosing Spondylitis Medication Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Ankylosing Spondylitis Medication Market Size (2018-2029) & (US$ Million)
Figure 17. Global Ankylosing Spondylitis Medication Sales (2018-2029) & (K Units)
Figure 18. Global Ankylosing Spondylitis Medication Average Price (US$/Unit) & (2018-2029)
Figure 19. Ankylosing Spondylitis Medication Report Years Considered
Figure 20. Ankylosing Spondylitis Medication Sales Share by Manufacturers in 2022
Figure 21. Global Ankylosing Spondylitis Medication Revenue Share by Manufacturers in 2022
Figure 22. The Global 5 and 10 Largest Ankylosing Spondylitis Medication Players: Market Share by Revenue in 2022
Figure 23. Ankylosing Spondylitis Medication Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 24. Global Ankylosing Spondylitis Medication Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 25. North America Ankylosing Spondylitis Medication Sales Market Share by Country (2018-2029)
Figure 26. North America Ankylosing Spondylitis Medication Revenue Market Share by Country (2018-2029)
Figure 27. United States Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. Canada Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. Europe Ankylosing Spondylitis Medication Sales Market Share by Country (2018-2029)
Figure 30. Europe Ankylosing Spondylitis Medication Revenue Market Share by Country (2018-2029)
Figure 31. Germany Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. France Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. U.K. Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Italy Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Russia Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Asia Pacific Ankylosing Spondylitis Medication Sales Market Share by Region (2018-2029)
Figure 37. Asia Pacific Ankylosing Spondylitis Medication Revenue Market Share by Region (2018-2029)
Figure 38. China Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Japan Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. South Korea Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. India Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Australia Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. China Taiwan Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Southeast Asia Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Latin America Ankylosing Spondylitis Medication Sales Market Share by Country (2018-2029)
Figure 46. Latin America Ankylosing Spondylitis Medication Revenue Market Share by Country (2018-2029)
Figure 47. Mexico Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Brazil Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Argentina Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Middle East & Africa Ankylosing Spondylitis Medication Sales Market Share by Country (2018-2029)
Figure 51. Middle East & Africa Ankylosing Spondylitis Medication Revenue Market Share by Country (2018-2029)
Figure 52. Turkey Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Saudi Arabia Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. UAE Ankylosing Spondylitis Medication Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. Global Sales Market Share of Ankylosing Spondylitis Medication by Type (2018-2029)
Figure 56. Global Revenue Market Share of Ankylosing Spondylitis Medication by Type (2018-2029)
Figure 57. Global Ankylosing Spondylitis Medication Price (US$/Unit) by Type (2018-2029)
Figure 58. Global Sales Market Share of Ankylosing Spondylitis Medication by Application (2018-2029)
Figure 59. Global Revenue Market Share of Ankylosing Spondylitis Medication by Application (2018-2029)
Figure 60. Global Ankylosing Spondylitis Medication Price (US$/Unit) by Application (2018-2029)
Figure 61. Ankylosing Spondylitis Medication Value Chain
Figure 62. Ankylosing Spondylitis Medication Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
